Saturday, October 24, 2015

Q3 2015 Earnings Call Tuesday Morning


Of course, we will cover it -- but we expect an in-line quarter with solid results for Keytruda® uptake.

We do expect Keytruda will be eclipsed by BMS's Opdivo®, overall though. Here are the details for the call:

. . . .Merck will hold its third-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 27. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Investors, journalists and the general public may access a live audio webcast of the call on Merck’s website at http://www.merck.com/investors/events-and-presentations/home.html. A replay of the webcast will be available at approximately 11:00 a.m. EDT on Oct. 27 and will remain on the website for 12 months. The sales and earnings news release and supplemental financial disclosures also will be available in the Newsroom and Investor sections of the company’s website at www.merck.com.

Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 42222255. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 42222255. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call. . . .


And. . . O/T space science post scriptum -- this is interesting, indeed -- between Cygnus and Lyra. Sleep tight, and/or good morning, one and all!

No comments: